ATE384793T1 - Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen - Google Patents

Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen

Info

Publication number
ATE384793T1
ATE384793T1 AT00962125T AT00962125T ATE384793T1 AT E384793 T1 ATE384793 T1 AT E384793T1 AT 00962125 T AT00962125 T AT 00962125T AT 00962125 T AT00962125 T AT 00962125T AT E384793 T1 ATE384793 T1 AT E384793T1
Authority
AT
Austria
Prior art keywords
dna fragments
corresponding dna
chlamydia antigens
chlamydia
strain
Prior art date
Application number
AT00962125T
Other languages
English (en)
Inventor
Andrew Murdin
Raymond Oomen
Joe Wang
Pamela Dunn
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE384793T1 publication Critical patent/ATE384793T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT00962125T 1999-09-20 2000-09-15 Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen ATE384793T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15465299P 1999-09-20 1999-09-20

Publications (1)

Publication Number Publication Date
ATE384793T1 true ATE384793T1 (de) 2008-02-15

Family

ID=22552195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00962125T ATE384793T1 (de) 1999-09-20 2000-09-15 Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen

Country Status (9)

Country Link
US (2) US7314869B2 (de)
EP (1) EP1220925B8 (de)
JP (1) JP4667694B2 (de)
AT (1) ATE384793T1 (de)
AU (1) AU783547B2 (de)
CA (1) CA2385325C (de)
DE (1) DE60037900T2 (de)
NZ (1) NZ517952A (de)
WO (1) WO2001021804A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011180A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING POMP91A PROTEIN OF $i(CHLAMYDIA)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
NZ512730A (en) * 1998-12-04 2003-12-19 Univ Manitoba A immunization procedure against chlamydia infection using an attenuated bacteria comprsing a plasmid with a major outer membrane protein (MOMP) from chlamydial
KR20100132086A (ko) 1998-12-08 2010-12-16 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
NZ514140A (en) 1999-03-12 2001-09-28 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
JP4695763B2 (ja) 1999-05-03 2011-06-08 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
JP4667694B2 (ja) 1999-09-20 2011-04-13 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
JP4864264B2 (ja) * 1999-12-22 2012-02-01 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
WO2001085972A2 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化
AU2004291575A1 (en) * 2003-11-21 2005-06-02 Sanofi Pasteur Limited Immunization against Chlamydia infection
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259595C (en) 1996-07-12 2010-11-30 University Of Manitoba Dna immunization against chlamydia infection
US6579854B1 (en) * 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
DE69834194T2 (de) * 1997-06-23 2007-03-29 Loke Diagnostics Aps Oberfläche-exponierte proteine von chlamydia pneumoniae
DE69841894D1 (de) 1997-11-21 2010-10-21 Merck Serono Biodevelopment Sa Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
WO1999027105A2 (en) * 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
EP2218730A1 (de) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Genomsequenz von Chlamydia trachomatis sowie Polypeptide, Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
WO2000024765A2 (en) 1998-10-28 2000-05-04 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
KR20100132086A (ko) 1998-12-08 2010-12-16 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
JP4695763B2 (ja) 1999-05-03 2011-06-08 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
JP4667694B2 (ja) 1999-09-20 2011-04-13 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
JP4864264B2 (ja) 1999-12-22 2012-02-01 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
WO2001046225A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020082402A1 (en) 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE389020T1 (de) 2000-04-21 2008-03-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US20040254130A1 (en) 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001085972A2 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化

Also Published As

Publication number Publication date
NZ517952A (en) 2004-01-30
EP1220925A1 (de) 2002-07-10
AU783547B2 (en) 2005-11-10
US20050002944A1 (en) 2005-01-06
JP4667694B2 (ja) 2011-04-13
DE60037900T2 (de) 2009-02-12
JP2003510050A (ja) 2003-03-18
US7662391B2 (en) 2010-02-16
EP1220925B8 (de) 2008-04-23
DE60037900D1 (de) 2008-03-13
EP1220925B1 (de) 2008-01-23
CA2385325A1 (en) 2001-03-29
WO2001021804B1 (en) 2001-05-10
US20050220805A1 (en) 2005-10-06
AU7398500A (en) 2001-04-24
CA2385325C (en) 2012-04-10
US7314869B2 (en) 2008-01-01
WO2001021804A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
ATE463575T1 (de) Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
IL211037A (en) Antigen @ reactant @ with @ serum @ hyper
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE542829T1 (de) Impfstoff
WO2003049762A3 (en) Immunisation against chlamydia trachomatis
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
ATE500843T1 (de) Streptococcus pneumoniae proteine und impfstoffe
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE60120621D1 (de) Lawsonia intracellularis Impfstoff
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
AU2003288510A1 (en) Immunizing fish against viral infection
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
NO20020615L (no) Vaksine
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
BR0207447A (pt) Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
WO2005048918A3 (en) Anthrax vaccine
WO2004073604A3 (en) Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
DK1227840T3 (da) Adjuverede, genetiske vacciner
DE60234772D1 (de) Gruppe-b streptococcus antigene und entsprechende dna-fragmente
WO2001036455A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001036457A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1220925

Country of ref document: EP